Merck/Eisai's Cancer Combo Therapy Ambition Dashed Once Again, Companies Throw Towel On Head & Neck Trial
Portfolio Pulse from Vandana Singh
Merck & Co Inc and Eisai Ltd have announced the discontinuation of the Phase 3 LEAP-010 trial evaluating Keytruda plus Lenvima for recurrent or metastatic head and neck squamous cell carcinoma. The decision was made after the therapy failed to show an improvement in overall survival in the second analysis. This follows the discontinuation of the LEAP-017 and LEAP-003 trials earlier this year and the LEAP-002 trial last year.
August 25, 2023 | 3:58 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Eisai's stock may be negatively impacted by the discontinuation of the LEAP-010 trial.
The discontinuation of the LEAP-010 trial is a setback for Eisai, which could negatively impact investor sentiment and lead to a decrease in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Merck's stock may be negatively impacted by the discontinuation of the LEAP-010 trial.
The discontinuation of the LEAP-010 trial is a setback for Merck, which could negatively impact investor sentiment and lead to a decrease in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100